Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs).

Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.

The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company.

Coya recent data in ALS seems under appreciated by the market and upcoming data in Alzheimer's offers the opportunity to confirm the early signals of efficacy in neurological conditions.

Coya Therapeutics went public this week, making it the last IPO of the year. Meanwhile, LiveOne announced that Courtside Group filed a registration statement with the SEC for its planned spin-out and special dividend to LiveOne's stockholders.